I found this article fascinating. As an engineer, I can see the logic that is being proposed here. It makes me wonder what better drug solutions could be identified if we all joined something like the UK biobank. I live in Thailand and will try and investigate what is happening here.
Even with the data, do you think the trial environment in the UK is capable? I'm blown away by how few trials we have here. American counterparts with the same terminal cancer as my husband have access to trial upon trial upon trial, they have access to named patient and compassionate access. In the UK, to obtain an immuno drug combo which has shown astounding results for the majority colon cancer patients even with liver involvement is nigh on impossible. I'm struggling as a lay person to understand why the trial landscape here is so sparse and approvals process so deadly slow, even for drugs that will most likely be approved by the fda soon. Even the UK govt websites listing trials is poor. I'm curious to know why we don't get trials here, even if you have all the data at your fingertips, do you really think it would translate into trials across the UK?
Beyond identifying drug targets, researchers now use "polygenic risk scores" (PRS) to predict a patient's unique reaction to a drug before they take it, potentially ending the era of "trial and error" prescribing.
I found this article fascinating. As an engineer, I can see the logic that is being proposed here. It makes me wonder what better drug solutions could be identified if we all joined something like the UK biobank. I live in Thailand and will try and investigate what is happening here.
Even with the data, do you think the trial environment in the UK is capable? I'm blown away by how few trials we have here. American counterparts with the same terminal cancer as my husband have access to trial upon trial upon trial, they have access to named patient and compassionate access. In the UK, to obtain an immuno drug combo which has shown astounding results for the majority colon cancer patients even with liver involvement is nigh on impossible. I'm struggling as a lay person to understand why the trial landscape here is so sparse and approvals process so deadly slow, even for drugs that will most likely be approved by the fda soon. Even the UK govt websites listing trials is poor. I'm curious to know why we don't get trials here, even if you have all the data at your fingertips, do you really think it would translate into trials across the UK?
Beyond identifying drug targets, researchers now use "polygenic risk scores" (PRS) to predict a patient's unique reaction to a drug before they take it, potentially ending the era of "trial and error" prescribing.